TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1859757

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Thiopentone and Propofol combination
Number of subjects: 120
Study: 6981173

Group type: EXPERIMENTAL
Intervention: Intravenous trimethoprim (TMP) 150 mg/m2 and sulfamethoxazole (SMZ) 750 mg/m2 every 8 hr
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravenous trimethoprim (TMP) and sulfamethoxazole (SMZ)
Number of subjects: 37
Study: 31526557

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C (1,500 mg every 6 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30239259

Group type: EXPERIMENTAL
Intervention: CBT infused with motivational interviewing (MI-CBT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Motivational language
Number of subjects: 85

Group type: COMPARATOR
Intervention: Self-reported motivation
Number of subjects: 85
Study: 28691174

Group type: EXPERIMENTAL
Intervention: Overall school climate
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: School climate subscale of engagement
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: School climate subscale of environment
Number of subjects: 500
Study: 25639601

Group type: EXPERIMENTAL
Intervention: Tweeting about sexism (public tweeters)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tweeting about sexism (private tweeters)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (three groups)
Number of subjects: 0
Study: 23969918

Group type: EXPERIMENTAL
Intervention: One-step self-etching adhesive (OSSE)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse adhesive (TSER)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Simplified ethanol-wet bonding technique (EWBT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study: 20924813

Group type: EXPERIMENTAL
Intervention: Multicomponent cognitive behavioral group intervention
Number of subjects: 540
Study: 19717699

Group type: EXPERIMENTAL
Intervention: Invasive therapeutic procedures
Number of subjects: 0
Study: 17322149

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (BIBR 1048)
Number of subjects: 287
Study: 15145015

Group type: EXPERIMENTAL
Intervention: Hand-sewn cervical esophagogastric anastomosis
Number of subjects: 63

Group type: COMPARATOR
Intervention: Circular stapled cervical esophagogastric anastomosis
Number of subjects: 63
Study: 12029403

Group type: EXPERIMENTAL
Intervention: Prone Positioning (PP) for 4 hours once daily until patients could sit in an armchair
Number of subjects: 51

Group type: COMPARATOR
Intervention: Supine Positioning (SP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Prone Positioning (PP)
Number of subjects: 51
Study: 9617717

Group type: EXPERIMENTAL
Intervention: Sinemet CR (chronic release formulation of levodopa/carbidopa)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7656190

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: streptokinase (SK)
Number of subjects: 35

Group type: COMPARATOR
Intervention: ST response
Number of subjects: 35

Group type: COMPARATOR
Intervention: ST response before 120 mins
Number of subjects: 35

Group type: COMPARATOR
Intervention: ST trends
Number of subjects: 35
Study: 1779440

Group type: EXPERIMENTAL
Intervention: Aqueous acupuncture (2 to 5 ml of 20% glucose solution injected into Ho‐Ku (LI 4) and Yang‐Ling‐Chuan (GB 34))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 12
Study: 7249557

Group type: EXPERIMENTAL
Intervention: Smoking a cigarette
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intermittent inhalations of charcoal
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oropharyngeal and laryngeal anaesthesia with lignocaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Filtration of particulate matter from cigarette smoke
Number of subjects: 23
Study: 30592371

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 1.5 mg twice daily starting on day 8
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (Tacrolimus - TAC)
Number of subjects: 140
Study: 28585903

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily for 30 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Aspirin 81 mg daily for 30 days
Number of subjects: 300
Study: 26206864

Group type: EXPERIMENTAL
Intervention: Sertraline plus higher-intensity, progressive aerobic exercise (S+PAE)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Sertraline plus lower-intensity, non-progressive exercise (S+NPE)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sertraline alone
Number of subjects: 121
Study: 24447007

Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' Conduct Problems Prevention Program (ER) for 3 intensive years plus 2 booster years
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 245
Study: 21926383

Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces
Number of subjects: 2081

Group type: COMPARATOR
Intervention: Control group (no braces)
Number of subjects: 2081
Study: 18854549

Group type: EXPERIMENTAL
Intervention: Two-weekly oxaliplatin 85 mg/m(2) + continuous intravenous infusion (CIV) of 5‐FU without LV or two‐weekly bolus and CIV 5‐FU + LV (LV5FU2)
Number of subjects: 725

Group type: COMPARATOR
Intervention: 5‐FU CIV or LV5FU2 alone
Number of subjects: 725
Study: 17407646

Group type: EXPERIMENTAL
Intervention: Analogue basal-bolus insulin (insulin detemir plus insulin aspart)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human basal-bolus insulin (Neutral Protamine Hagedorn plus human soluble insulin)
Number of subjects: 0
Study: 15570501

Group type: COMPARATOR
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS) at 110% motor threshold, 1 Hz, 2000 stimuli/day over 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11136280

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 2 weeks (Group A)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 2 weeks (Group B)
Number of subjects: 140

Group type: COMPARATOR
Intervention: OAC for 1 week (Group C)
Number of subjects: 140
Study: 9688487

Group type: EXPERIMENTAL
Intervention: LLETZ under local paracervical anesthesia (Group B)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Multiple cervical punch biopsies (Group A)
Number of subjects: 119
Study: 8047827

Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2783352

Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride formula
Number of subjects: 12

Group type: COMPARATOR
Intervention: Long-chain triglyceride formula
Number of subjects: 12
Study: 192405

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens
Number of subjects: 21
Study: 30770244

Group type: EXPERIMENTAL
Intervention: Lidocaine/Ketorolac combination (1.5 mg/kg lidocaine and 30 mg ketorolac)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ketorolac (30 mg)
Number of subjects: 150
Study: 30511473

Group type: EXPERIMENTAL
Intervention: Lamotrigine extended-release formulation (test group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing strengths of lamotrigine (reference group)
Number of subjects: 0
Study: 28040315

Group type: EXPERIMENTAL
Intervention: Metabolic control assessed with the latest annual glycosylated haemoglobin (HbA1c)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cardiovascular comorbidity
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Risk factors
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Adherence to Mediterranean diet
Number of subjects: 129
Study: 25577145

Group type: EXPERIMENTAL
Intervention: Ventilated group (VG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-ventilated group (NVG)
Number of subjects: 30
Study: 23529719

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Nonresurfacing
Number of subjects: 1725
Study: 21142756

Group type: EXPERIMENTAL
Intervention: Analogical transfer approach (experimental group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional approach (control group)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study: 19514188

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Qiuxu (GB 40)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Electroacupuncture at Tianshu (ST 25)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Follow-up survey after 3 months
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Follow-up survey after 6 months
Number of subjects: 275
Study: 17467513

Group type: EXPERIMENTAL
Intervention: Valsartan (40-160 mg per day)
Number of subjects: 3081

Group type: COMPARATOR
Intervention: Control (other treatment without angiotensin receptor blockers)
Number of subjects: 3081
Study: 15011856

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (ARCO 2000 ES unit, group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Injection sclerotherapy (diluted adrenalin 1:10,000 plus polidocanol 1%, group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 11724223

Group type: EXPERIMENTAL
Intervention: Tramadol/APAP (75 mg/650 mg)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Tramadol (75 mg)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: APAP (650 mg)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1197
Study: 8990057

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8484506

Group type: EXPERIMENTAL
Intervention: Intranasal meperidine (6 sprays, 27 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous meperidine (6 mL, 27 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intranasal NaCl 0.9% (6 sprays)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous NaCl 0.9% (6 mL)
Number of subjects: 60
Study: 2892582

Group type: EXPERIMENTAL
Intervention: Bevantolol (200 mg) + Hydrochlorothiazide (25 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 22
Study: 29534407

Group type: EXPERIMENTAL
Intervention: 0-50% preset ASIR-V (an interval of 10%) applied in groups A-F, with group E showing 40% preset ASIR-V as optimal.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Group E (40% preset ASIR-V)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Groups B-F (with varying preset ASIR-V)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Groups A-F
Number of subjects: 180
Study: 26404844

Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OT) administration (40 IU)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 24394704

Group type: EXPERIMENTAL
Intervention: Flavanol-rich soluble cocoa product (7.5 g per serving, 2 servings per day, providing 45.3 mg flavanols per day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Milk (control group)
Number of subjects: 44
Study: 22426371

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent influenza subunit vaccine Fluad (®)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Doubling H3N2 antigen content
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Higher doses of MF59 (®)
Number of subjects: 357
Study: 21040545

Group type: EXPERIMENTAL
Intervention: Directly-observed therapy (DOT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Self-administered therapy (SAT)
Number of subjects: 216
Study: 18536785

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T (APC-8015)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16640103

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV) 800 mg three times daily with zidovudine (AZT)/lamivudine (3TC) twice daily
Number of subjects: 103

Group type: COMPARATOR
Intervention: Indinavir/ritonavir (IDV/RTV) 800/100 mg twice daily with zidovudine (AZT)/lamivudine (3TC) twice daily
Number of subjects: 103
Study: 12894981

Group type: EXPERIMENTAL
Intervention: Multiparameter approach using Nakagami and K distributions for classification of breast masses
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Combination of the discriminant with the level of suspicion values of the radiologist
Number of subjects: 99
Study: 10905437

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemonucleolysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8796408

Group type: EXPERIMENTAL
Intervention: Single dose of muscle relaxant
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Continuous skeletal muscle paralysis for longer than 24 h
Number of subjects: 53

Group type: COMPARATOR
Intervention: No paralysis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Paralysed patients
Number of subjects: 53
Study: 1636580

Group type: COMPARATOR
Intervention: Standard dose (1200 mg/day for 14 days)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High dose (2400 mg/day for 7 days)
Number of subjects: 92
Study: 4032694

Group type: EXPERIMENTAL
Intervention: Ordinary dose fentanyl (15 mcg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Moderate dose fentanyl (37 mcg/kg)
Number of subjects: 26
Study: 31123801

Group type: EXPERIMENTAL
Intervention: Ecdysterone supplementation
Number of subjects: 46
Study: 30408115

Group type: EXPERIMENTAL
Intervention: CAB LA 600 mg IM every 8 weeks
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CAB LA 800 mg IM every 12 weeks
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CAB LA (both doses)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CAB LA
Number of subjects: 199

Group type: COMPARATOR
Intervention: PBO (placebo)
Number of subjects: 199
Study: 26537369

Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride ointment (MHO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erythromycin eye ointment (EEO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no topical antibiotics)
Number of subjects: 40
Study: 25163993

Group type: EXPERIMENTAL
Intervention: practical training of body contact
Number of subjects: 20

Group type: COMPARATOR
Intervention: parent counseling on body contact
Number of subjects: 20
Study: 22333852

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analogues (PGAs) administered over 24 weeks
Number of subjects: 75
Study: 20833738

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a target dose of 2 g/day
Number of subjects: 105

Group type: COMPARATOR
Intervention: Azathioprine (AZA) at a target dose of 2 mg/kg/day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both MMF and AZA
Number of subjects: 105
Study: 17466479

Group type: EXPERIMENTAL
Intervention: Low-field MRI (0.2 T)
Number of subjects: 27

Group type: COMPARATOR
Intervention: High-field MRI (1.5 T)
Number of subjects: 27
Study: 16338269

Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Multiple antihypertensive agents
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 15904
Study: 11889016

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide pulse therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 26
Study: 10567782

Group type: EXPERIMENTAL
Intervention: gemifloxacin 10 min before Maalox
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: gemifloxacin 3 h after Maalox
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: gemifloxacin 2 h before Maalox
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: gemifloxacin administration
Number of subjects: 16
Study: 7595910

Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 25
Study: 1697822

Group type: EXPERIMENTAL
Intervention: Etoposide with doxorubicin (Group 1: n = 17)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Etoposide with carminomycin (Group 2: n = 8)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BACOP (Group 3: n = 14)
Number of subjects: 39
Study: 220733

Group type: EXPERIMENTAL
Intervention: Adriamycin (40 mg/m2) given every 4 weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adriamycin combined with 5‐Fluorouracil, Vincristine and Prednisolone
Number of subjects: 65

Group type: COMPARATOR
Intervention: Historical group (38 patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No treatment group (15 patients)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adriamycin and Prednisolone (both regimens)
Number of subjects: 65
Study: 31675184

Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization of the median, radial, and ulnar nerves
Number of subjects: 72

Group type: COMPARATOR
Intervention: Robotic-assisted passive movement treatment
Number of subjects: 72
Study: 31684960

Group type: EXPERIMENTAL
Intervention: Random selection method using aerial imagery; 202 grids selected from 10 neighbourhoods for interviews.
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Proposed method for household sampling.
Number of subjects: 202
Study: 28556578

Group type: EXPERIMENTAL
Intervention: Bilberry diet (BB; n=15)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Strawberry, raspberry, and cloudberry diet (SRC; n=20)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control diet (n=12)
Number of subjects: 47
Study: 25439086

Group type: EXPERIMENTAL
Intervention: Early systematic physical rehabilitation
Number of subjects: 63

Group type: COMPARATOR
Intervention: No physical rehabilitation (Control)
Number of subjects: 63
Study: 23486935

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (coach-focused workshop with additional supervisions)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Regular intervention (coach-focused workshop without additional supervisions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (unsupervised website)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High adherence to the 11+ programme
Number of subjects: 31
Study: 22042958

Group type: EXPERIMENTAL
Intervention: paclitaxel plus sequential trastuzumab weekly for 52 weeks (arm B)
Number of subjects: 4087

Group type: EXPERIMENTAL
Intervention: paclitaxel plus concurrent trastuzumab for 12 weeks followed by trastuzumab for 40 weeks (arm C)
Number of subjects: 4087

Group type: COMPARATOR
Intervention: doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by paclitaxel weekly for 12 weeks (arm A)
Number of subjects: 4087
Study: 19589307

Group type: EXPERIMENTAL
Intervention: Multimedia education tool
Number of subjects: 31
Study: 17005077

Group type: EXPERIMENTAL
Intervention: Nourishing yin and Unblocking meridians Recipe (NUR) combined with opioid analgesics
Number of subjects: 84

Group type: COMPARATOR
Intervention: Opioid analgesics alone
Number of subjects: 84
Study: 15161788

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 217
Study: 11549098

Group type: EXPERIMENTAL
Intervention: Ezetimibe (daily doses ranging from 0.25 to 10 mg for 12 weeks)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 9664584

Group type: EXPERIMENTAL
Intervention: Cerebral infarction patients
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intracerebral hemorrhage patients
Number of subjects: 6
Study: 8112928

Group type: EXPERIMENTAL
Intervention: neutral hypnosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: deep relaxation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pleasant dissociated 'out of body' imagery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: focused analgesia of the hand
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 3418289

Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 3860

Group type: EXPERIMENTAL
Intervention: Doctor's letter only
Number of subjects: 3860

Group type: COMPARATOR
Intervention: General practitioner consultation rates
Number of subjects: 3860
Study: 31628524

Group type: EXPERIMENTAL
Intervention: Metformin plus first-line chemotherapy (paclitaxel plus carboplatin)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel plus carboplatin)
Number of subjects: 44
Study: 29162120

Group type: EXPERIMENTAL
Intervention: deltamethrin + PBO LLIN
Number of subjects: 16

Group type: COMPARATOR
Intervention: deltamethrin LLIN
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: deltamethrin + PBO LLIN (rainy/high transmission season)
Number of subjects: 16

Group type: COMPARATOR
Intervention: deltamethrin LLIN (rainy/high transmission season)
Number of subjects: 16
Study: 25240692

Group type: EXPERIMENTAL
Intervention: DHA-enriched high oleic canola oil (CanolaDHA)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional canola oil (Canola)
Number of subjects: 114
Study: 23269119

Group type: EXPERIMENTAL
Intervention: Exercise (6-min treadmill exercise)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy nonasthmatic nonatopic term children
Number of subjects: 42
Study: 22011016

Group type: EXPERIMENTAL
Intervention: Real rTMS (high-frequency over left dorsolateral prefrontal cortex for 25 minutes) plus individualized speech therapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo rTMS plus individualized speech therapy
Number of subjects: 3